A 16-month-old girl diagnosed with osteopetrosis underwent an unrelated, partially matched (with major mismatch at A locus) cord blood stem cell transplant. Twelve months later she developed severe acute autoimmune hemolytic anemia (AIHA). Immunophenotype analysis of lymphocyte subsets 8 months post transplant showed a low number of T lymphocytes, with normal subsets, and with NK cells and B lymphocytes within normal ranges. When the hemolytic anemia developed, the lymphocytes subsets changed and analysis showed higher numbers of B lymphocytes than previously, lower CD3
immune diseases that involves mainly skin, mucosal and serosal surfaces, liver, lung and hematopoietic system. Godder et al 1 reported several cases of cGVHD presenting as acute autoimmune hemolytic anemia (AIHA) in mismatched related bone marrow transplant patients. AIHA has been reported after bone marrow transplantations with an incidence between 3% and 12.5%. [1] [2] [3] [4] A few cases have also been reported after cord blood grafts. 5, 6 Descriptions of immune reconstitution in patients with autoimmune complications after transplantation where progenitors have derived from different sources may help in the understanding of such immune complications, including cGHVD. We report a severe immune-mediated hemolytic anemia and the associated lymphocyte subset findings, manifesting as the first cGVHD, in a patient diagnosed with osteopetrosis, 12 months after an unrelated cord blood stem cell transplant.
Case report
A 16-month-old girl with osteopetrosis underwent an unrelated cord blood transplant. The patient and donor were blood group B+, and were partially HLA-matched. The patient was A 0101/03,6801 , B 0801/05,5101 , DRB1 0301,0405/29 . The donor unit was A 0101/03,2601/09 , B 0801/05,5101 , DRB1 0301,0405/29 . The patient received a conditioning regimen consisting of busulfan (16 mg/kg total dose in divided doses p.o. every 6 h days −9 to −6), cyclophosphamide (60 mg/kg i.v. days −5 and −4), anti-thymocyte globulin (15 mg/kg every day from day −5 to −1) and methylprednisolone (1 mg/kg/day from day −5 to −1). For GVHD prophylaxis she received cyclosporine and methylprednisolone according to the Eurocord protocol for unrelated cord blood transplant. A cord blood unit containing 0.96 × 10 6 CD34 + cells/kg recipient weight was infused. G-CSF 50 g/day from day +1 until day +14 was administered. Neutrophil engraftment was evident on day +14 and Ͼ20 000 platelets/l were reached on day +20. She developed hyper-acute liver and skin GVHD grade III, treated with methylprednisolone (4 mg/kg/day) with good response. Steroid treatment was tapered off by day +37 without evidence of GVHD recurrence. Chimerism studies performed on bone marrow by short tandem repeat analysis on day +15 showed full donor engraftment. Other complications during the post-transplant period were Enterobacter cloacae bacteremia and two episodes of Staphylococcus epidermidis bacteremia, all treated and resolved. Severe mucositis secondary to chemotherapy, and hypertension secondary to cyclosporine also occurred in this period.
The post-transplant course was complicated by bronchopneumonia 8 and 10 months later.
Twelve months after transplant, with no signs of chronic GVHD, she was tapering off the cyclosporine. She then developed severe anemia (hemoglobin 5.3 g/dl), with hemolytic features (indirect bilirubin 3.7 mg/dl and direct bilirubin 0 g/dl). The direct antiglobulin (Coombs') test was strongly positive for IgG, but negative for C3d. The eluate and serum of the patient reacted on the indirect antiglobulin test with the red blood cells tested (11 panel cells). Leukopenia and thrombocytopenia were never observed.
Peripheral blood is routinely collected in our patients to study immune reconstitution by immunophenotype analysis of lymphocyte subsets. Eight months post-transplant it showed a low number of T lymphocytes, with normal subsets and with NK cells and B lymphocytes within the normal ranges. When the hemolytic anemia developed, the lymphocytes subsets changed and analysis showed low CD3 + T lymphocytes (inversion of CD4/CD8 ratio 45%/47.6%), and an abnormal proportion of T lymphocyte subsets. Higher numbers of B lymphocytes (CD19 + 56.9%) than expected were also found (Table 1) . Chimerism studies showed full donor engraftment.
She was treated with methylprednisolone 5 mg/kg/day and intravenous immunoglobulin 1 g/kg/day for 5 days. She continued cyclosporine. Transfusion of three units of packed red blood cells was needed. After 10 days of treatment, the hemolytic anemia was controlled (Figure 1 ). Over the next 2 months she developed two episodes of Staphylococcus aureus pneumonia. Recurrent pneumothoraces were also observed on chest X-ray and she required insertion of a chest tube. The Table 1 Immunophenotype analysis of lymphocyte subsets in peripheral blood before, during and after hemolytic anemia hemolytic anemia was stable over this period. Due to these infections, she was weaned off the intensive immunosuppressive treatment. While on methylprednisolone 2 mg/kg/day and with no cyclosporine for 4 days, her hemolytic anemia worsened (Hb 4.3 g/dl). Reinstitution of intravenous immunoglobulin at the same dose, and treatment with cyclophosphamide (50 mg/day for 3 days) and vincristine (1 mg, only one dose) were attempted. She required red blood cell transfusions five times, but the acute hemolysis continued until the cyclos-porine was restarted 23 days after discontinuing treatment ( Figure 2 ). Then hemolytic anemia improved over the next 2 months while the methylprednisolone was weaned and she is currently on low-dose treatment (0.5 mg/kg/day). Over this period, when the AIHA was being treated, she developed extensive skin cGVHD and recurrent pneumothoraces. Although cyclosporine treatment was continued she is no longer anemic, and immunophenotype analysis of the lymphocytes subsets are within the normal ranges (Table 1) , with a positive direct antiglobulin test.
Discussion
Allogeneic hematopoietic transplantation is the only curative therapy for osteopetrosis. 7 Chronic graft-versushost disease (cGVHD) is a serious long-term complication in such patients and often presents involving skin, mucosal and serosal surfaces, liver or lung. Some authors have considered cGVHD to be a manifestation of autoimmunity, but the pathophysiological basis for autoimmunity after hematopoietic transplantation is not clearly defined. 2, 8 Cases describing findings relating to autoimmunite complications should help to understand their pathophysiology.
AIHA has been described after manipulated and unmanipulated bone marrow transplantation, 1,3,4 but has been described in only two cord blood stem cell transplants, both of which were only partially matched. 5, 6 Several reports have considered a dysregulation between B and T cells to be the source of immune problems after transplant. 1, 3, 4 The absence of certain T cell clones or a differential reconstitution of various T cell subsets, for instance a recently described CD25
+ T cell clone, 9 would lead to dysregulation of B cells, and production of autoantibodies. It could explain why this complication is less frequent when higher numbers of T cells are infused, as occurs in unmanipulated peripheral blood progenitor cell transplants, and hence Bone Marrow Transplantation immunophenotype analysis of lymphocyte subsets could help to understand this complication. Godder et al 1 reported immunophenotype analysis of the lymphocyte subsets to be within the normal ranges when AIHA developed. We found low T lymphocytes before AIHA developed in our patient, and an abnormal proportion of CD3 + T lymphocyte subsets, with inversion of the CD4/CD8 ratio. CD19
+ B lymphocytes were higher than expected when the hemolytic features were observed. Currently, with no hemolytic activity, immunophenotype analysis is normal.
After AIHA developed, and while immunosuppression was being tapered, she developed extensive cGVHD. This led us to consider AIHA as the first manifestation of cGVHD as has been previously described.
1 cGVHD is the clinical manifestation of aberrant immune reconstitution after transplantation. 8 Whether cGVHD should be considered as an autoimmune or an alloimmune disease is controversial. 2, 8 AIHA is considered to be an immune dysregulation probably related to abnormal reconstitution of T and B cells in these patients. Autoimmune diseases may be evaluated as manifestations of cGVHD if other clinical signs of cGVHD appear later.
Regarding treatment response, the first published surveys 2-4 described poor response to conventional treatment, but other series published later describe a better prognosis. 1 In most cases, treatment other than conventional approaches is needed to resolve the acute complications. However, addition of intensive immunosuppression to the post-transplant immunodeficiency may worsen the prognosis. Most patients had died of infectious complications during immunosuppressive therapy. In this patient, the secondary infectious complications led to the weaning of immunosuppressive treatment, but the AIHA worsened, and cyclosporine was then added to treat this new episode. Some authors have suggested a pathogenic role of cyclosporine in autoimmunity after transplantation.
3,4 However, others have described AIHA resistant to steroid treatment that only responded to cyclosporine. 10 In our patient, AIHA only improved when cyclosporine was reinstituted. The role of cyclosporine is often controversial in these patients, but in the present case, it resulted in cure of the AIHA.
In conclusion, AIHA may be the first manifestation of cGVHD. AIHA may represent the abnormal reconstitution of immunity after hematopoietic transplantation which is the basis of cGVHD. Aggressive immunosuppressive treatment with intensive measures against infection may lead to improved treatment results.
